Weight-loss drug users are stopping treatment too soon: study
30% Quit Weight-Loss Drugs Early: Why?
A study by the Blue Cross Blue Shield Association reveals that over 30% of patients using GLP-1 weight-loss drugs like Ozempic and Wegovy discontinue their treatment prematurely, often within just four weeks, despite needing a minimum of 12 weeks for effective results. Young adults and those in underserved regions are particularly prone to early dropout. Side effects and high costs are significant factors in discontinuation, with those paying less than $60 monthly more likely to persist with their regimen. This early cessation often leads to regaining two-thirds of the weight lost.
What percentage of patients stop taking GLP-1 drugs like Ozempic and Wegovy within four weeks according to the Blue Cross Blue Shield Association report?
According to the Blue Cross Blue Shield Association report, more than 30% of patients stop taking GLP-1 drugs like Ozempic and Wegovy within the first four weeks of their treatment4.
What are the common side effects that might lead patients to discontinue their GLP-1 medication treatment before six weeks?
The common side effects that might lead patients to discontinue their GLP-1 medication treatment before six weeks include nausea, diarrhea, stomach pain, vomiting, and constipation. These side effects are typically experienced early on in the treatment and may cause patients to stop taking the medication. Additionally, cost can also be a factor in the discontinuation of weight-loss drugs, as high copays and coinsurance can make the medications less accessible for some individuals.